Özlem ÖZBAĞÇIVAN, Sevgi AKARSU, Şebnem AKTAN, Necla DOLAŞ

Possible triggering factors and comorbidities in newly diagnosed autoimmune bullous diseases

Background/aim: The distribution and the demographic, etiological, and clinical features of autoimmune bullous diseases (ABDs) vary according to geographic regions of the world. The limited number of reported studies in Turkey are mostly retrospective and generally include only pemphigus. The aim of our study was to evaluate the demographic data, clinical features, associated triggering factors, and comorbidities in patients newly diagnosed with ABDs. Materials and methods: In this descriptive and prospective study, the demographic data, inhabited regions, smoking and drinking habits, presence of comorbidities, and specific and general potential triggering factors of ABDs considered by the patients were examined. Furthermore, the distribution of lesions and autoimmune bullous skin disorder intensity scores were recorded. Results: Of the total 59 ABD patients, 26 (44.1%) were diagnosed with pemphigus, 25 (42.4%) were diagnosed with pemphigoid, and 8 (13.5%) were diagnosed with dermatitis herpetiformis. Although there were some differences between the subgroups of ABDs, the onset of the disease was associated with a triggering factor (stress, foods, physical trauma, chemical agents, ultraviolet rays, medications, infections, malignancies, and pregnancy, in a decreasing frequency) in 96.6% of the patients. Autoimmune diseases, neuropsychiatric disorders, diabetes mellitus, and hypertension were found to be statistically significantly higher in the pemphigoid group compared to the pemphigus and dermatitis herpetiformis groups. Conclusion: Evaluation of triggering factors and comorbidities before starting treatment may assist in controlling the disease more swiftly and reducing the side effects of treatment in the management of ABDs. However, to evaluate the frequency and significance of our findings in order to determine whether they are statistically significant or not, we suggest a multicenter prospective clinical trial, which would include control groups and a higher number of patients for each of the disease groups and clinical subtypes.

PDF

___

1. Sticherling M, Erfurt-Berge C. Autoimmune blistering diseases of the skin. Autoimmun Rev 2012; 11: 226-230.
2. Alpsoy E, Akman-Karakas A, Uzun S. Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid. Arch Dermatol Res 2015; 307: 291- 298.
3. Uzun S, Durdu M, Akman A, Gunasti S, Uslular C, Memisoglu HR, Alpsoy E. Pemphigus in the Mediterranean region of Turkey: a study of 148 cases. Int J Dermatol 2006; 45: 523-528.
4. Bozdag K, Bilgin I. Epidemiology of pemphigus in the western region of Turkey: retrospective analysis of 87 patients. Cutan Ocul Toxicol 2012; 31: 280-285.
5. Tükenmez Demirci G, Mansur AT, Aydıngöz İE. Risk factors in pemphigus. Türkderm 2011; 45: 140-155 (in Turkish with abstract in English).
6. Gül Ü, Kılıç A, Külcü Çakmak S, Soylu S, Gönül M. Clinical and demographical features of autoimmune bullous diseases: a retrospective analysis of 85 patients. Türkderm 2014; 48: 7-12 (in Turkish with abstract in English).
7. Daye M, Mevlitoğlu İ, Esener S. Bullous disorders in Konya: a study of 93 cases. Türkderm 2013; 47: 200-204 (in Turkish with abstract in English).
8. Ruocco V, Ruocco E, Lo Schiavo A, Brunetti G, Guerrera LP, Wolf R. Pemphigus: etiology, pathogenesis, and inducing or triggering factors: facts and controversies. Clin Dermatol 2013; 31: 374-381.
9. Lo Schiavo A, Ruocco E, Brancaccio G, Caccavale S, Ruocco V, Wolf R. Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies. Clin Dermatol 2013; 31: 391-399.
10. Bonciani D, Verdelli A, Bonciolini V, DErrico A, Antiga E, Fabbri P, Caproni M. Dermatitis herpetiformis: from the genetics to the development of skin lesions. Clin Dev Immunol 2012; 2012: 239691.
11. Fedeles F, Murphy M, Rothe MJ, Grant-Kels JM. Nutrition and bullous skin diseases. Clin Dermatol 2010; 28: 627-643.
12. Pfütze M, Niedermeier A, Hert M, Eming R. Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J Dermatol 2007; 17: 4-11.
13. Alonso-Llamazares J, Gibson LE, Rogers RS 3rd. Clinical, pathologic, and immunopathologic features of dermatitis herpetiformis: review of the Mayo Clinic experience. Int J Dermatol 2007; 46: 910-919.
14. Wohl Y, Brenner S. Pemphigus in Israel - an epidemiologic analysis of cases in search of risk factors. Isr Med Assoc J 2003; 5: 410-412.
15. Valikhani M, Kavusi S, Chams-Davatchi C, Daneshpazhooh M, Barzegari M, Ghiasi M, Abedini R. Pemphigus and associated environmental factors: a case-control study. Clin Exp Dermatol 2007; 32: 256-260.
16. Tsankov N, Vassileva S, Kamarashev J, Kazandjieva J, Kuzeva V. Epidemiology of pemphigus in Sofia, Bulgaria. A 16-year retrospective study (19801995). Int J Dermatol 2000; 39: 104- 108.
17. Brenner S, Tur E, Shapiro J, Ruocco V, DAvino M, Ruocco E, Tsankov N, Vassileva S, Drenovska K, Brezoev P et al. Pemphigus vulgaris: environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire. Int J Dermatol 2001; 40: 562-569.
18. Bastuji-Garin S, Joly P, Lemordant P, Sparsa A, Bedane C, Delaporte E, Roujeau JC, Bernard P, Guillaume JC, IngenHousz-Oro S et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 2011; 131: 637-643.
19. Chen YJ, Wu CY, Lin MW, Chen TJ, Liao KK, Chen YC, Hwang CY, Chu SY, Chen CC, Lee DD et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Brit J Dermatol 2011; 165: 593-599.
20. Wöhrl S, Hemmer W, Focke M, Rappersberger K, Jarisch R. Histamine intolerance-like symptoms in healthy volunteers after oral provocation with liquid histamine. Allergy Asthma Proc 2004; 25: 305-311.
21. Kluk J, Goulding JM, Bhat J, Finch TM. Drug-induced bullous pemphigoid: cases triggered by intravenous iodine and etanercept. Clin Exp Dermatol 2011; 36: 871-873.
22. Zhang F, Yang B, Lin Y, Chen S, Zhou G, Wang G, Chen X, Zhang Y, Tian H, Yu M et al. Dermatitis herpetiformis in China: a report of 22 cases. J Eur Acad Dermatol 2012; 26: 903- 907.
23. Ljubojevic S, Lipozenčić J. Autoimmune bullous diseases associations. Clin Dermatol 2012; 30: 17-33.
24. Marzano AV, Tedeschi A, Spinelli D, Fanoni D, Crosti C, Cugno M. Coagulation activation in autoimmune bullous diseases. Clin Exp Immunol 2009; 158: 31-36.
25. Kavala M, Kural E, Kocaturk E, Zindanci I, Turkoglu Z, Can B. The evaluation of thyroid diseases in patients with pemphigus vulgaris. Scientific World Journal 2012; 2012: 146897.
26. Esmaili N, Mortazavi H, Noormohammadpour P, Boreiri M, Soori T, Vasheghani Farahani I, Mohit M. Pemphigus vulgaris and infections: a retrospective study on 155 patients. Autoimmune Diseases 2013; 2013: 834295.
27. Lehman JS, Khunger M, Lohse CM. Infection in autoimmune bullous diseases: a retrospective comparative study. J Dermatol 2013; 40: 613-619.
28. Gambichler T, Segert H, Höxtermann S, Schmitz L, Altmeyer P, Teegen B. Neurological disorders in patients with bullous pemphigoid: clinical and experimental investigations. J Eur Acad Dermatol 2015; 29: 1758-1762.
29. Lai YC, Yew YW, Lambert WC. Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis. J Eur Acad Dermatol 2016; 30: 2007-2015.
30. Wills AJ, Turner B, Lock RJ, Johnston SL, Unsworth DJ, Fry L. Dermatitis herpetiformis and neurological dysfunction. J Neurol Neurosur Ps 2002; 72: 259-261.